A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

The patent, granted under No. 2276473, is titled “Gastroretentive Drug Delivery for Carbidopa / Levodopa” and is currently scheduled to remain in force until April 2029.

Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders ...

Crexont is a novel, oral formulation that contains immediate-release granules of carbidopa and levodopa and extended-release beads of levodopa.

AbbVie already markets a carbidopa and levodopa combination with Duopa. That med launched in 2015 as a novel delivery system meant to skirt common downfalls of oral carbidopa/levodopa treatment.

The FDA approved an oral extended-release formulation of levodopa and carbidopa known as IPX203 (Crexont) to treat Parkinson's disease, Amneal Pharmaceuticals announced Wednesday.

The FDA recently rejected ND0612, a 24-hour-a-day liquid levodopa and carbidopa infusion from the Mitsubishi Tanabe Pharma subsidiary NeuroDerm.

DUOPA (carbidopa and levodopa) enteral suspension is a prescription medicine used for treatment of advanced Parkinson's disease. DUOPA contains two medicines: carbidopa and levodopa.

A study of entacapone administered with carbidopa/levodopa CR showed less robust enhancement of levodopa AUC, probably due to the more rapid absorption and elimination of entacapone compared with ...

Dhivy is a prescription medication that contains a combination of carbidopa and levodopa for the treatment of Parkinson's disease.